ClinicalTrials.gg
CompletedNCT03803618Updated May 17, 2023

Dengue Effectiveness Study in the Philippines

An observational study in Dengue, Severe Dengue and Virologically Confirmed Dengue, sponsored by University of the Philippines. Completed at 4 sites in Philippines. Open to participants aged 9 Years to 14 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-17.

Primary conditionSevere DengueRegistry: DengueReclassifiedWhy we changed it
Registry
Dengue — the first condition term the registry derived for this study.
ClinicalTrials.gg
Severe Dengue
Why
  1. The study's listed conditions name Severe Dengue, a narrower term within Dengue.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of the Philippines · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
2,081
Ages
9 Years to 14 Years
Sex
All
01

Study summary

This is an observational study that aims to determine the effectiveness of a tetravalent dengue vaccine (CYD-TDV) when given through a community-based immunization program against hospitalized and /or severe virologically confirmed dengue.

Read the detailed description

This is a matched case-control study. Cases will be children who are admitted with a clinical suspicion of dengue at the study hospitals and were eligible to have received the dengue vaccine during the mass immunization. The outcome of interest is hospitalized and/or severe virologically-confirmed dengue and the exposure is receipt of the dengue vaccine. Each case will be matched to two controls who were also eligible to have received the dengue vaccine and lives in the same area as the case. Cases and controls will be matched by age and sex.

02

Conditions studied

  • Dengue
  • Severe Dengue
  • Virologically Confirmed Dengue

Browse trials for

03

In context

Severe Dengue Reclassified

65 studies on the registry are indexed under Severe Dengue; 5 are open to participants now.

This study's enrollment of 2,081 is above the median of 667 across 13 observational studies indexed under Severe Dengue.

Browse Severe Dengue studies →

Lead sponsor

University of the Philippines is the lead sponsor of 26 studies on the registry; 4 are open to participants now.

Compared within Severe Dengue, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dengue. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
9 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Individuals to be enrolled in the study as probable cases will be admitted patients in the hospital study sites who are residents of the area, eligible to have received the dengue vaccine at the time of the initiation of community-based dengue vaccination program, and suspected to have dengue.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

CASE-CONTROL STUDIES

  • For a suspected case to be enrolled in the study, he/she should:

    • Provide signed and assent (as applicable)
    • Be within the age group eligible to receive the dengue vaccine at the time of mass vaccination (i.e. no condition that would have made him/her ineligible for dengue vaccination)
    • Be admitted in any of the participating hospitals for suspected dengue
    • Have ≤5 days history of fever.
    • For the case to be included in the analysis, the participant must meet all the inclusion criteria above plus have virologically-confirmed dengue infection by RT-PCR
  • For controls to be recruited into the study, he/she should:

    • Provide signed informed consent and assent (as applicable)
    • Be age and sex-matched to the case
    • Be from the same community as the matched case
    • Be eligible to have received dengue vaccine during the community-based dengue immunization campaign in 2017 (i.e. no condition that would have made him/her ineligible for dengue vaccination)
    • Have had no episode of clinically-diagnosed or laboratory-confirmed dengue fever from the start of the community -based dengue immunization campaign to the focal time (the date of onset of dengue fever in the matched case)
    • Should not have been previously recruited as a control.

Exclusion criteria

Exclusion Criteria:

  • Any subject whose parent/guardian refuse to provide and/or assent.
  • In addition, the following conditions automatically exclude children from the dengue mass immunization:

    • Children \<9 years or adults older than 45 years of age
    • Anyone who is allergic or has had an allergic reaction to a prior dose or to any component of the dengue vaccine
    • Recipient of blood product in the last 3 months
    • individuals, due to but not limited to genetic defects, infection, or therapies that affect the immune system such as high-dose or chemotherapy
    • Recipient of any vaccine within the past month
    • History of bleeding disorder
    • Pregnant or breastfeeding women
    • Enrolled in dengue vaccine Phase 3 clinical study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
2,081 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Confirmed dengue case

    Dengue cases who are 9-14 years old during the dengue mass vaccination program in Cebu with \<5 days history of fever, admitted in the participating hospitals with dengue virus confirmation by RT-PCR

  • Control

    Age and sex matched neighborhood controls

06

What researchers measure

Primary outcomes

  1. hospitalized and / or severe virologically confirmed dengue

    The primary outcome are children who are hospitalized and/or severe virologically confirmed dengue

    Time frame: 5 years

07

Study locations

4 sites
  • Cebu Provincial Hospital - Balamban
    Balamban, Cebu, Philippines
  • Cebu Provincial Hospital - Bogo
    Bogo City, Cebu, Philippines
  • Cebu Provincial Hospital - Danao
    Danao, Cebu, Philippines
  • Eversley Childs Sanitarium and General Hospital
    Mandaue City, Cebu, Philippines
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03803618
Lead sponsor
University of the Philippines
Collaborators
Sanofi Pasteur, a Sanofi Company, Research Institute for Tropical Medicine, Philippines
Responsible party
Sponsor
First posted
Jan 14, 2019
Start date
Sep 1, 2017
Primary completion
Nov 30, 2022
Completion
Apr 30, 2023
Last update
May 17, 2023

Study contacts

Jacqueline L. Deen, MD
principal investigator · UPM - NIH, Institute of Child Health and Human Development

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion